Clinical Research On Cardiotoxicity Of Endostar In Patients With Non-small Cell Lung Cancer

Objective:To research the cardiotoxicity of endostatin (recombineant human endostatin) in the patients with advanced non-small cell lung cancer (NSCLC) and its related risk factors. Methods:A total of 188 patients with advanced NSCLC and chemotherapy, who were confirmed by histopathological diagnosis, had no serious cardiovascular disease and the chance of operation Among them 92 cases were treated with Docetaxel+Nedaplatin+Endostar (experimental group),96 cases with Docetaxel+Nedaplatin (control group), no signifi-cant difference between two groups in general clinical data (P> 0.05), every 21d for a cycle, at least observe 4 cycles. Recorded the change of ECG, blood pressure and symptoms of cardiovascular system during chemotherapy, The positive were determined myocardial enzyme and troponin-T. Results: Comparing the two groups, there are statistically significant difference in cardia-ctoxicity between the experimental group and the control group after chemotherapy (P<0.05). In experimental group, there were statistically significant differences in cardiactoxicity between before and fter chemotherapy (P<0.05), and Change of ECG was statistically significant In first cycles and second cycles aftre chemotherapy (P<0.05), including 8 cases (8.6%) had myocardial enzyme changes; but in control group, cardiactoxicity differences before and after chemotherapy had no statistical significance(P>0.05). In texperimental group, found that cardiotoxicity of endostatin incidence rates high to low were:ECG changes.cardiovascular system symptoms and abnormal blood pressure, and further logistic regression analysis showed that, the difference of cardiotoxicity between different age andhistory of cardio vascular disease were significant (P<0.05), the difference of different nationalities and stage、diabetes were not significant (P>0.05). Conclusion:Cardiotoxicity of endostatin was mainly the change of ECG,cardiovascular system symptoms and abnormal blood pressure. And ECG changes are the most common performance. Older age, cardiovascular disease are the risk factors for cardiactoxicity of endostatin.